Cresco Labs Inc.

AI-generated fair value estimate for this company.

Method: 10-year EBITDA-derived FCF DCF: $90M normalized owner-earnings base (roughly half of ~$160M annualized adjusted EBITDA run-rate, haircut for heavy federal 280E cash taxes and maintenance capex); 0% annual growth years 1-5 (declining state cannabis pricing offsetting unit growth); 1% years 6-10; 14% discount rate for cannabis regulatory/credit risk; 1.5% terminal growth; -$500M net debt (~$590M total debt less ~$40M cash); 383.8M shares outstanding (derived from market cap/price).

Reasoning: Cresco Labs is a profitable-at-the-EBITDA-level but heavily indebted, 280E-taxed cannabis multistate operator; a conservative owner-earnings haircut and high discount rate reflect regulatory uncertainty, while flat near-term growth reflects wholesale price compression offsetting volume gains.